企業プロフィール
CRISPR Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- CRSP
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Switzerland with major U
株価パフォーマンス
54.28 USD (+1.36%)
終値
最終更新: 2026年8月17日
5.02B USD
時価総額
株価変動の要因
As of Aug 17, 2026, CRSP closed up 1.36% at $54.28. No new same-company headline was identified in the current news window.
企業概要
Gene-Based Medicine Platform
CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies.
CASGEVY
CASGEVY is an ex vivo CRISPR-edited autologous stem-cell therapy approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Vertex leads manufacturing and commercialization, while the companies share program economics.
In Vivo Liver Editing
The liver-directed portfolio includes CTX310 against ANGPTL3 for severe lipid disorders, CTX340 against angiotensinogen for refractory hypertension, CTX321 against LPA and CTX460 against SERPINA1 for alpha-1 antitrypsin deficiency. These programs use lipid nanoparticles to perform editing directly in patients.
Zugo-Cel
Zugo-cel is an off-the-shelf CD19 CAR-T therapy engineered with CRISPR for immune evasion and potency. It is being evaluated across rheumatologic, hematologic and neurologic autoimmune diseases as well as B-cell malignancies.
RNA Therapeutics
Through a collaboration with Sirius Therapeutics, the company is developing CTX611, a long-acting Factor XI siRNA for thromboembolic disorders. The candidate is in Phase 2 testing in patients undergoing total knee arthroplasty.
Regenerative Medicine
CTX213 is a deviceless, gene-edited beta-cell replacement candidate for type 1 diabetes. The program uses edited induced pluripotent stem cells to create unencapsulated precursor islet cells intended to restore insulin production.
今後のカタリスト
- FDA review milestones for the pediatric CASGEVY submission covering patients ages 5–11.
- CTX340 clinical-trial initiation planned in the first half of 2026 and CTX460 trial initiation planned for mid-2026.
- Clinical update from the Phase 1b CTX310 program expected in the second half of 2026.
- Updates from the zugo-cel autoimmune and B-cell malignancy programs expected in the second half of 2026.
- Phase 2 CTX611 update expected in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。